Blue Horseshoe Stocks

ARO, RMTI, PHOT & Extended Watchlist

Aeropostale, Inc. ARO

At the beginning of August, ARO began to experience a substantial sell-off that would cause the stock to fall from the $15-range to less than $8 at the beginning of this month. We are standing at the ready this morning as we’ve observed some northward pre-market trading, with shares changing hands for as much as 10.13. The significant gaps on the chart being filled could provide not only opportunities on the stock side of things, but in the trading of options contracts as well.

The 10/19 $9.00 Calls are of particular interest to us; Closing at .35 yesterday, and with this morning’s gap-up activity, these calls could open up as much as 100% In that event, we would be looking for a consolidation before getting our feet wet.

Rockwell Medical, Inc. RMTI

RMTI would make a nice intraday move for us after its appearance in yesterday’s morning report, running from a low of 8.75 and reaching its peak at 11.80, good enough for a 35% gain.

Following the high, the stock came back as low as 9.85. Moving we are looking for the stock to hold support at its previous swing low of 8.75. In the meantime the company released an encouraging PR today announcing the completion of an important step in getting a new kidney drug to market, that appears to be contributing to yet another gap-up situation today.

WIXOM, MI–(Marketwired – Sep 17, 2013) – Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, today announced the U.S. Food & Drug Administration (FDA) accepted the proposed proprietary trade name Triferic^™for the Company’s investigational iron-delivery drug, previously known as Soluble Ferric Pyrophosphate (SFP), which is intended for treating iron deficiency in chronic kidney disease patients receiving hemodialysis. A request for proprietary name review for Triferic^™will be filed with the New Drug Application (NDA) submission.>>>FULL STORY

GroLife, Inc. PHOT

We had another gainer in PHOT yesterday, as the stock jumped from .046 to .061, affording us the opportunity at a 33% intraday rip. Since 08/30 when we re-mentioned PHOT, it has been as low as .0318, which makes yesterday’s high a move of 93%

For almost a year now, we’ve placed a strong focus on marijuana-related stocks, publishing several reports, and doing the most recent followup at the end of August. The industry has, and we believe, will continue to bring us profits in the future. It’s for that reason we suggest everyone keep a marijuana stock watchlist of their own. We have only just begun to realize the potential for this up-and-coming sector, which is certain to be a high-growth area for years to come.

Extended Watchlist:
AGEN, NBS, BCRX, RGDO, SUTR, DNDN, MATR, SD

RMTI, PHOT & Extended Watchlist

Rockwell Medical, Inc. RMTI

We mentioned RMTI in Friday’s extended watchlist, and it turned out to be a good decision on our part. After opening at a low of 8.75, the price surged ahead to touch 10.20, marking an opportunity at intraday gains of up to 17%

We’re going to leave RMTI on our radars as we kick off a fresh week of trading, as the stock appears to be gapping up this morning, (presently above Friday’s high, trading at 10.50 premarket). The stock also traded high volume on Friday, so we want to monitor the situation for any further gains the current flux of momentum might provide.

Growlife, Inc. PHOT

PHOT had a good day on Friday as well, breaking a recent double-top, posting gains on increased volume. The stock hit a high .0477, which from the low following our most recent mention of this play (.0318), represents a 50% move.

We’ve got this and other marijuana-related stocks on continuous watch since the USDOJ announcement that the federal government would not be interfering with individual states that have voted to legalize the plant for both medical and personal use.

Extended Watchlist:
EXMT, IGLD, INO, BZ, ZQK, GOGO

FREE, VCLK & Extended Watchlist

FreeSeas, Inc. FREE

We mentioned FREE on Tuesday after it set off our irregular volume scanner. We’re still watching this stock, as it has managed to achieve higher lows and higher highs every day since then while maintaining much of that volume and momentum. We generally consider a setup like this to be a bullish signal, so we’ll be monitoring the situation as we close out the week. So far, from Tuesday’s low (.2213) to yesterday’s high (.3346), our total possible gain on this play in just three sessions amounts to 51%

We mentioned that our main areas of resistance here were at .33 and .38, and that statement still holds true.

VCLK Options
We were looking at the 09/21 $21 Calls on VCLK a couple of weeks back, so let’s look at what they’ve done for us in the meantime. At the time they were trading in the .60-.80 range, and have since hit a high 1.45, reached at yesterday’s close. We are going to want to keep an eye on these calls heading into their expiration at the end of next week. Provided VCLK continues to fill its recent gap-down (pointed out in our previous report) and push us further into the money, we should continue to see gains from these contracts.

Extended Watchlist:
OCLR, CTIC, ONCY, SGMO, RMTI, CUR

AXXE | Axxess Pharma, Inc. | Today’s Focus

Axxess Pharma, Inc. AXXE

We’re putting AXXE on our radars this morning, a new play with a chart that appears to have potential. As always when we focus on a new company, we’d first like to take a few minutes to familiarize ourselves with the business behind the stock.

Axxess Pharma has an expansive line which includes twenty-three prescription and non-prescription strength products, which are used in the treatment of a variety of ailments, including but not limited to: iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, and joint pain.

The company has been taking steps to make these products available to the public at an affordable price.

AXXE recently signed an agreement with a Mexican pharma company that will facilitate the distribution of its Soropon product to the Mexican population, which, according to President and CEO Dr. Daniel Bagi, is ” three times that of Canada’s and has a higher birth rate than Canada. AXXE is extremely pleased with the market possibilities in Mexico for Soropon and we anticipate robust sales for Soropon in Mexico, starting in 2014.”

That and more was covered yesterday when we conducted an Exclusive Interview with Dr. Bagi via our sister site, Stock Traders Talk. It covered a lot of important things, so be sure to take a few minutes to check that out on StockTradersTalk.com when it becomes available this afternoon!

AXXE EXCLUSIVE INTERVIEW
Available after 1:00PM today, only on Stock Traders Talk!

Now to go over the AXXE chart, for which we’ve provided the following video presentation:

Axxess has been awfully busy of late, making several news announcements already this month. Between its active approach to shareholder outreach via press release, as well as the CEO making the time to take part in our interview, we can see that this company places a high emphasis on transparency and visibility. To that end, if you read ahead to the PRs, we find that AXXE is actually making preparations for an uplisting to the OTC Bulletin Board.

SEPTEMBER PRESS RELEASES:

09.11.13: Axxess Pharma Inc. Initiates Next Step Towards Bulletin Board (OTCBB) Listing

09.09.13: AXXESS Pharma Inc. Signs Agreement With Top Mexican Pharmaceutical Company

09.04.13: Axxess Pharma Inc. Announces US Board Certified Cardiologist, Dr. Fred Maese as Senior Consultant

09.02.13: Axxess Pharma Inc. Announces MOU to Acquire Leading Canadian OTC Healthcare Company

More Info is available at:
www.axxesspharmainc.com

HNR, CETV & Extended Watchlist

Harvest Natural Resources, Inc. HNR

HNR set off our scanner this morning as this energy stock appears to be gapping up heavily in pre-market trading. Harvest announced this morning that it had entered into negotiations to sell the company’s Venezuelan assets, and spin off its remaining assets into a new company, a move that the CEO believes the proposed sale “affords the Company and its shareholders the ability to reap the benefits of our exceptional portfolio in the near term.” We’ll certainly be watching, as HNR is currently up 35% (a/o 8:30am).

In addition to this morning’s press release (below), the company will be holding a conference call tomorrow for anyone interested in learning more about the proposed transaction and its ramifications. To access the conference call, dial 800-344-6698 or 785-830-7979, five to ten minutes prior to the start time. At that time you will be asked to provide the conference number, which is 3073565. A recording of the conference call will also be available for replay at 719-457-0820, passcode 3073565 through September 17, 2013.

HOUSTON, Sept. 11, 2013 /PRNewswire via COMTEX/ — Harvest Natural Resources, Inc. (NYSE: HNR) today announced it has entered into exclusive negotiations with Pluspetrol Venezuela S.A., an entity belonging to one of the leading exploration and production companies in Latin America, to sell the outstanding shares of Harvest. >>> FULL REPORT

CEM Enterprises CETV

We first called CETV on May 10th after it popped up on our Form-4 scan. At the time it was trading at 2.67, and in the roughly four months since that time, it has yet to dip below that price.

We are placing it back on watch for further gains as it is approaching its recent high of 4.85 (reached at the end of August), which represented a gain of 82% from our bottom. We’re interested to see if the stock can now break past that previous swing high for added gains. Conditions on the chart suggest this as a possibility, as you can see, the RSI is rumbling toward the powerzone, we have a potential Golden Cross of the 50 & 200DMA currently setting up.

Extended Watchlist:
AQUM, VTUS, PSTI, DVAX